Search

Search Bar
01/01/2026 EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis
Marzo-Ortega, H, Harrison, SR, Fragoulis, GE, Michelena, X, Macía-Villa, C, Aydin, SZ, Balanescu, A, Bertheussen, H, Bundy, C, Chimenti, MS, Gisondi, P, Glintborg, B, Gossec, L, Kalyoncu, U, Lubrano, E, Nagy, G, Wagenaar, W, Puig, L, Queiro, R, Rahman, P, Shumnalieva, R, Soriano, ER, van den Bosch, F, Sande, MMGHV, Sepriano, A, Machado, PM, Siebert, S. EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. ANNALS OF THE RHEUMATIC DISEASES. 2026; 85(1)DOI:10.1016/j.ard.2025.10.002. PMID:41168056. IF:20.600(Q1/1D).
01/12/2025 ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
Grau-Pérez, M, Ciudad, C, Molina-Leyva, A, Martorell, A, Vilarrasa, E, Albert, I, Garcias-Ladaria, J, Melgosa, FJ, Rivera, R, Campos, M, Haselgruber, S, Ochando, G, Pascual, JC, García-Ruiz, R, Alfageme, F. ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa. DERMATOLOGY. 2025; 241(5-6)DOI:10.1159/000546647. PMID:40587963. IF:2.700(Q2/4D).
01/12/2025 REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS
Ferrer, AL, Belinchón, I, Serra, MC, Clua, MG, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/12/2025 UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS
Ferrer, AL, Belinchón, I, Serra, MC, Martínez, LE, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/12/2025 HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS
Strober, B, Puig, L, Lebwohl, MG, Lakshminarasimhan, B, Khan, SA, Pillai, N, Kappelhoff, B, Weatherill, A, Warren, RB. HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/11/2025 Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) still be part of the Baseline Series?
Fernández, CPH, Borrego, L, Arnau, AMG, Sánchez, TS, Carrillo, JMC, Ninet, VZ, Baldrich, ES, Miquel, FJM, Salvador, JFS, Guijarro, SC, Gilo, AS, García, PM, Triviño, FN, Romero, FT, Serna, MR, Ninot, GM, González, IR, de la Fuente, EG, Nieto, MAP, Guillén, PSP, Pérez, JS, Rodríguez, JJP, Ortega, MEG, Pérez, RG, Doval, IG, Descalzo, MAG. Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) still be part of the Baseline Series?. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2024.10.063. PMID:40024601. IF:(Q/D).
01/09/2025 Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series
Mateu-Arrom, L, Martin, R, Expósito-Serrano, V, Alvarez-Abella, A, Serra-Baldrich, E, Spertino, J. Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.05.022. PMID:40480489. IF:(Q/D).
01/09/2025 Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups
Feldman, SR, Sanz, LP, Girolomoni, G, Jo, SJ, Jung, H, Jung, J. Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).